Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Paris, France, 28 August: A German team has developed a completely new non-invasive method to identify heart failure. It consists of an "electronic nose" which could make the "smelling" of heart failure possible. The projet was presented at the ESC Congress 2011 today. “The early detection of chronic heart failure (CHF) through periodical screening facilitates early treatment application” said investigator Vasileios Kechagias from the University Hospital Jena. Heart failure is a common, costly, disabling and potentially deadly condition. In developed countries, around 2% of adults suffer from heart failure, but in those over the age of 65, this increases to 6–10%. Mostly due to costs of hospitalisation, it is associated with high health expenditure. Heart failure is associated with significantly reduced physical and mental health, resulting in a markedly decreased quality of life. Although some people survive many years, progressive disease is associated with an overall increased mortality and morbidity. “We conducted a daily screening of patients with different degrees of heart failure. For the study, eligible patients were enrolled after informed consent, and the collected data was anonymous. Measurements were made in collaboration with the University of Applied Sciences, Jena. The participating physicians of the Department of Internal Medicine I, University Hospital of Jena, were responsible for patient recruitment and analysis of clinical data,” explained Kechagias.
In particular, the relevant laboratory parameters for heart failure (BNP, minerals, creatinine, blood gas analysis) were collected and a clinical assessment of heart failure based on the available parameters (clinical history, laboratory, echocardiography, and exercise stress test) was performed. In 2010, we screened a total of 250 patients and included 126 in the clinical study. In the course of the study, testing was optimized through a standardized skin preparation. The assignment of patients to the different groups (no heart failure vs moderate heart failure vs decompensated heart failure) was performed by physicians blinded for the measured values through the electronic nose.
Two groups were formed with CHF patients: one with decompensated (n=27) heart failure and one with compensated (n=25) heart failure. As clinical manifestation of the decompensated heart failure investigators evaluated the marked limitation of any activity where the patient is comfortable only at rest (Class III) or the state in which any physical activity brings on discomfort and symptoms occur at rest (Class IV). Furthermore they screened a control group of patients without heart failure symptoms (n=28). Then the measurement with the "electronic nose" randomly took place, from 10 cycles of 3 min. each and a subsequent offline-data-analysis.
The “electronic nose” system consists of an array of three thick-film metal oxide based gas sensors with heater elements. Each of the sensors has a slightly different sensitivity to various odorant molecular types. Interactions between molecules and the sensor are caused by reactions with oxygen on the heated sensor surface leading to a change of the free charge carrier concentrations and thus to a change in conductivity in the metal oxide layer. The odour components are divided by a statistical analysis into two principal components. In all patients, data acquisition was possible. The patients with decompensated heart failure could be divided from compensated heart failure with 89% sensitivity and 88% specificity. Cardiovascular drug use was not different in these groups. On the other hand, patients without heart failure (control group) were different from the patients with heart failure in the principal-component analysis (89% sensitivity and 84% specificity).
Further work is in progress to identify the responsible components.
Our primary objective is to create and establish a minimal invasive method, which will help to rapidly screen, diagnose, group and monitor the CHF.
Contributors: V. Kechagias1, K. Witt2, S. Reulecke2, C. Fischer2, R. Surber1, H.R. Figulla1, A. Voss2 (1) University Hospital Jena, Department of Internal Medicine I, Jena, Germany (2) Department of Medical Engineering and Biotechnology, University of Applied Sciences Jena, Jena, Germany
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2011. abstract N° 87192, “Smelling” heart failure, evaluation of an electronic nose The press release has been written by the investigator and edited by the ESC and does not necessarily reflect the opinion of the European Society of Cardiology.
About the European Society of Cardiology The European Society of Cardiology (ESC) represents more than 68,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2011 ESC Congress 2011 will take place from 27 to 31 August at the Parc des Expositions - Paris Nord Villepinte, France. Information on the scientific programme is available here. More information on ESC Congress 2011 is available from the ESC Press Office or contact us at email@example.com
© 2017 European Society of Cardiology. All rights reserved